Cytomedix (OTCQX:CMXI), a pioneer in biodynamic therapies, today announced that it has re-launched its AutoloGel chronic wound care system under the AurixTM brand. The formal launch of Aurix is an integral part of the Company's full scale marketing plan for the commercialization of Aurix in the multi-billion dollar U.S. chronic wound care market.
The Aurix System™ website (
www.aurixsystem.com) launched today in preparation for management's participation at The Symposium on Advanced Wound Care (SAWC) Fall Meeting, being held October 16-18, 2014 in Las Vegas, Nevada.
"Since April of this year we have been laser-focused on refining the marketing strategy and commercial model, including recruiting the sales team to successfully launch Aurix into the U.S. marketplace," said Dean Tozer, Chief Commercial Officer of Cytomedix. "With a direct sales team of nearly twenty representatives now in place in the hospital outpatient as well as Veterans Affairs settings, we are poised to begin full scale product promotion. The broad Aurix label provides clearance from the FDA for the product to treat multiple types of chronic wounds, which total more than 6 million wounds every year in the United States."
The Aurix System itself has not been changed in any way and will continue to offer physicians and patients a proven solution for hard to treat skin ulcers and wounds that can have significant impact on a patient's quality of life. Aurix is a biodynamic hematogel that harnesses a patient's innate healing mechanisms in order to jumpstart the healing process from deep within the wound bed.
Chief Executive Officer, Marin Rosendale added, "Over the last 10 months, Cytomedix has transformed its organizational focus, with an emphasis on developing the commercial capabilities necessary to support this re-launch. We have out-licensed non-core assets, closed our R&D facility and raised the necessary capital to build and equip a world-class commercial team. The launch of Aurix signals the first major milestone in this new commercial strategy."
About Aurix
Aurix is the first platelet and plasma therapy system to be cleared by the FDA for the management of ulcers and wounds of all types (diabetic foot ulcer, pressure ulcer, venous leg ulcer, etc.) and all severities (partial thickness, full thickness, and complex wounds). It can be used successfully on patients with tunneling, sinus tracts, bone and tendon exposure, and hardware exposure.
Unlike other cellular-based treatment options, Aurix is derived from a patient's own platelets and plasma (autologous). Once applied, the product goes to work, stimulating the natural healing process to form tissue to fill in wound defects and help reduce wound volume. Aurix produces visible results in days, not weeks and is effective at all stages of wound care for non-healing wounds.
Click to expand...